Lynnai's Instablog Welcome You’ve arrived here because of the huge potential gains to be had by investors trading OTC stocks. If you’d like to contact us for any reason please feel free and we will respond as soon as possible. Thanks Lynnai http://seekingalpha.com/user/700250/instablog (GILD, DVD, MG, NOAH, CLNO, PMI) Stock to Watch by CRWEFinance.com http://seekingalpha.com/instablog/700250-lynnai/204532-gild-dvd-mg-noah-clno-pmi-stock-to-watch-by-crwefinance-com?source=feed 204532  

 

 

Gilead Sciences, Inc. (Nasdaq:GILD) is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The mission of Gilead Sciences is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead Sciences has operations in North America, Europe and Asia Pacific.

 

Gilead Sciences yesterday announced that it has resolved all outstanding issues raised in a Warning Letter issued by the U.S. Food and Drug Administration (FDA) in September 2010 related to its San Dimas, California manufacturing facility.

The FDA notified Gilead yesterday that Gilead Sciences' response and the actions that have been adopted and implemented at the San Dimas site have sufficiently addressed the FDA's observations, which were primarily related to the manufacturing environment for AmBisome® (amphotericin B) liposome for injection, as well as general observations related to systems, procedures and controls focused on ensuring product quality at the San Dimas facility.

Gilead Sciences' products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of chronic angina; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems.

Gilead Sciences' products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular age-related macular degeneration; and Lexiscan/Rapiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Gilead Sciences' products under the Phase III clinical trials consist of Cobicistat, a pharmacoenhancer that is under evaluation as a boosting agent for HIV medicines; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; Integrase Single-Tablet, a 'Quad' regimen of elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine for the treatment of HIV/AIDS in treatment-naive patients; and Aztreonam for inhalation solution for the treatment of cystic fibrosis patients with Pseudomonas aeruginosa.

For more information about Gilead Sciences, please visit: www.gilead.com.
(Read more at: http://crwefinance.com/?p=19983)

]]> Thu, 11 Aug 2011 11:46:12 -0400  

 

 

Gilead Sciences, Inc. (Nasdaq:GILD) is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The mission of Gilead Sciences is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead Sciences has operations in North America, Europe and Asia Pacific.

 

Gilead Sciences yesterday announced that it has resolved all outstanding issues raised in a Warning Letter issued by the U.S. Food and Drug Administration (FDA) in September 2010 related to its San Dimas, California manufacturing facility.

The FDA notified Gilead yesterday that Gilead Sciences' response and the actions that have been adopted and implemented at the San Dimas site have sufficiently addressed the FDA's observations, which were primarily related to the manufacturing environment for AmBisome® (amphotericin B) liposome for injection, as well as general observations related to systems, procedures and controls focused on ensuring product quality at the San Dimas facility.

Gilead Sciences' products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of chronic angina; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems.

Gilead Sciences' products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular age-related macular degeneration; and Lexiscan/Rapiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Gilead Sciences' products under the Phase III clinical trials consist of Cobicistat, a pharmacoenhancer that is under evaluation as a boosting agent for HIV medicines; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; Integrase Single-Tablet, a 'Quad' regimen of elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine for the treatment of HIV/AIDS in treatment-naive patients; and Aztreonam for inhalation solution for the treatment of cystic fibrosis patients with Pseudomonas aeruginosa.

For more information about Gilead Sciences, please visit: www.gilead.com.
(Read more at: http://crwefinance.com/?p=19983)

]]> gild GILD DVD MG NOAH CLNO PMI (CTC, SGAE, EPD, CLNO, NTL) Notable Stock by CRWEFinance.com http://seekingalpha.com/instablog/700250-lynnai/204406-ctc-sgae-epd-clno-ntl-notable-stock-by-crwefinance-com?source=feed 204406 IFM Investments Limited (NYSE:CTC) a leading comprehensive real estate services provider and the exclusive franchisor for the CENTURY 21® brand in China, announced that it will report its unaudited financial results for the second quarter ended June 30, 2011, before the U.S. markets open on August 16, 2011.

Read more at http://crwefinance.com/?p=19978

]]> Thu, 11 Aug 2011 07:12:11 -0400 IFM Investments Limited (NYSE:CTC) a leading comprehensive real estate services provider and the exclusive franchisor for the CENTURY 21® brand in China, announced that it will report its unaudited financial results for the second quarter ended June 30, 2011, before the U.S. markets open on August 16, 2011.

Read more at http://crwefinance.com/?p=19978

]]> CTC SGAE EPD CLNO NTL (NHPR, EEP, GCA, ASX, CRWE) Noticeable Stock by CRWEFinance.com http://seekingalpha.com/instablog/700250-lynnai/204396-nhpr-eep-gca-asx-crwe-noticeable-stock-by-crwefinance-com?source=feed 204396 Today, health care in the United States is still among the most expensive in the world while in spite of decades of government financing and regulations, tens of millions of people are left uninsured. America's health care system is in desperate need of reform. Unfortunately, the reformers promise only more government interference all the while blaming the market for not providing adequate, cheap medical care.


Read more at http://crwefinance.com/?p=19979

]]> Thu, 11 Aug 2011 06:36:22 -0400 Today, health care in the United States is still among the most expensive in the world while in spite of decades of government financing and regulations, tens of millions of people are left uninsured. America's health care system is in desperate need of reform. Unfortunately, the reformers promise only more government interference all the while blaming the market for not providing adequate, cheap medical care.


Read more at http://crwefinance.com/?p=19979

]]> NHPR EEP GCA ASX CRWE (CRWE, VHI, MJS.V, WMS, SLW) Stock in Focus by CRWEFinance.com http://seekingalpha.com/instablog/700250-lynnai/204388-crwe-vhi-mjs-v-wms-slw-stock-in-focus-by-crwefinance-com?source=feed 204388 Crown Equity Holdings Inc. offers internet media-driven advertising services, which covers and connects a range of marketing specialties, as well as search engine optimization for clients interested in online media awareness. Crown Equity Holdings Inc., together with its digital network, currently provides electronic media services specializing in online publishing, which brings together targeted audiences and advertisers.

Read more at http://crwefinance.com/?p=19977

]]> Thu, 11 Aug 2011 06:26:17 -0400 Crown Equity Holdings Inc. offers internet media-driven advertising services, which covers and connects a range of marketing specialties, as well as search engine optimization for clients interested in online media awareness. Crown Equity Holdings Inc., together with its digital network, currently provides electronic media services specializing in online publishing, which brings together targeted audiences and advertisers.

Read more at http://crwefinance.com/?p=19977

]]> CRWE VHI MJS.V WMS SLW (RL, NHPR, OAS, EXAM, CLNO) Stock in Review by CRWEFinance.com http://seekingalpha.com/instablog/700250-lynnai/204385-rl-nhpr-oas-exam-clno-stock-in-review-by-crwefinance-com?source=feed 204385 Polo Ralph Lauren Corp (NYSE:RL) reported net income of $184 million, or $1.90 per diluted share, for the first quarter of Fiscal 2012, compared to net income of $121 million, or $1.21 per diluted share, for the first quarter of Fiscal 2011.

Read more at http://crwefinance.com/?p=19976

]]> Thu, 11 Aug 2011 06:25:09 -0400 Polo Ralph Lauren Corp (NYSE:RL) reported net income of $184 million, or $1.90 per diluted share, for the first quarter of Fiscal 2012, compared to net income of $121 million, or $1.21 per diluted share, for the first quarter of Fiscal 2011.

Read more at http://crwefinance.com/?p=19976

]]> RL NHPR OAS EXAM CLNO (SGAE, XCO, EGY, CRWE, HHC) Stock Highlights by CRWEFinance.com http://seekingalpha.com/instablog/700250-lynnai/204377-sgae-xco-egy-crwe-hhc-stock-highlights-by-crwefinance-com?source=feed 204377 Siga Resources Inc, founded in 2007, is based in South Lake Tahoe, California. Siga is a mineral resource exploration and development company. Siga's strategy targets properties that have the potential for near term production and early positive cash flow. Siga's general geographical interest is North and South America.


Read more at http://crwefinance.com/?p=19975

]]> Thu, 11 Aug 2011 06:16:53 -0400 Siga Resources Inc, founded in 2007, is based in South Lake Tahoe, California. Siga is a mineral resource exploration and development company. Siga's strategy targets properties that have the potential for near term production and early positive cash flow. Siga's general geographical interest is North and South America.


Read more at http://crwefinance.com/?p=19975

]]> SGAE XCO EGY CRWE HHC